Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1501-1509
Published online before print August 14, 2003, doi: 10.1161/01.ATV.0000090886.40027.DC
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
23/9/1501    most recent
01.ATV.0000090886.40027.DCv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allayee, H.
Right arrow Articles by Lusis, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allayee, H.
Right arrow Articles by Lusis, A. J.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1501.)
© 2003 American Heart Association, Inc.

Brief Reviews

Using Mice to Dissect Genetic Factors in Atherosclerosis

Hooman Allayee; Anatole Ghazalpour; Aldons J. Lusis

From the Departments of Human Genetics (H.A., A.J.L.); Microbiology, Immunology, and Molecular Genetics (A.G., A.J.L.); and Medicine (A.J.L.), and the Molecular Biology Institute (A.J.L.), David Geffen School of Medicine at UCLA, Los Angeles, Calif.

Reprint requests to Aldons J. Lusis, PhD, Department of Medicine, Division of Cardiology, 47-123 Center for the Health Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095. E-mail jlusis{at}mednet.ucla.edu

Series Editor: James Scott
ATVB in Focus

Lipoproteins, Inflammation, and Atherosclerosis

Previous Brief Reviews in this Series:

•Pennachhio LA, Rubin EM. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. 2003;23:529–534.
•Cullen P, Baetta R, Bellosta S, Bernini F, Chinetti G, Cignarella A, von Eckardstein A, Exley A, Goddard M, Hofker M, Hurt-Camejo E, Kanters E, Kovanen P, Lorkowski S, McPheat W, Pentikäinen M, Rauterberg J, Ritchie A, Staels B, Weitkamp B, de Winther M for the MAFAPS Consortium. Rupture of the atherosclerotic plaque: does a good animal model exist? 2003;23:535–542.


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowThe Quantitative Trait Locus...
 down arrowMapping Genes for...
 down arrowFrom QTL to Gene...
 down arrowThe Road Ahead
 down arrowConclusions
 down arrowReferences
 
The genes that contribute to common, complex forms of atherosclerosis remain largely unknown. Genetic studies in humans have, for the most part, focused on identifying genes that predispose to the traditional risk factors, such as lipid levels and blood pressure, but apart from rare, single-gene disorders, there have been few successes to date. The use of mice to dissect the complex genetic etiology of atherosclerosis offers a viable alternative to human studies, because experimental parameters, such as environment, breeding scheme, and detailed phenotyping, can be controlled. Herein we review how mouse genetics can lead to the identification of genes, some of which would otherwise not have been considered as candidates for atherosclerosis, and provide an overview of the prospects for successful gene discovery in the future.


Key Words: atherosclerosis • genetic factors


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowThe Quantitative Trait Locus...
 down arrowMapping Genes for...
 down arrowFrom QTL to Gene...
 down arrowThe Road Ahead
 down arrowConclusions
 down arrowReferences
 
Genetic factors contribute importantly to atherosclerosis in human populations, with a heritability of {approx}50%. Although there has been considerable success in identifying genes for rare disorders associated with atherosclerosis, our understanding of genes involved in the common forms is very incomplete. A large number of association studies with candidate genes have been performed, but few have been convincingly confirmed. Those that have been confirmed, including variations of hepatic lipase and HDL levels, apolipoprotein E (apoE) and LDL levels, apoCIII/apoAV and triglyceride levels, and paraoxonase 1 and myocardial infarction, as well as a handful of others, explain only a very small fraction of genetic susceptibility to atherosclerosis in humans. Clearly, a more complete understanding of the genetics of atherosclerosis would have important implications for diagnosis, treatment, and risk assessment (reviewed in Lusis et al1 and Lusis2).

In principal, there are 2 ways to assign genes to physiologic processes. The first, called "forward genetics," uses naturally occurring or induced mutations that affect the process. Usually, the underlying gene is identified by mapping the mutation with linkage analysis and then testing "positional candidates." Alternatively, if a known gene is suspected of playing a role in a physiologic process, then variations of the gene can be examined by association in cases versus controls, the "candidate gene" approach. The second strategy, termed "reverse genetics," involves the transgenic modification of a known gene, usually in a mouse or a rat, and then examining its effect on the physiologic process. Both forward and reverse genetics strategies have been crucially important for our field. In terms of forward genetics, the most important advances have come from human geneticists who have studied the rare mendelian disorders that perturb risk factors, such as lipid metabolism or blood pressure. For example, during the past few years, identification of genes for Tangier disease (ABCA1) and sitosterolemia (ABCG5 and ABCG8) has transformed our understanding of cholesterol transport. The forward genetics approach can also be applied to the dissection of complex genetic traits, which involve multiple genes and environmental influences.3 Here, progress has been relatively slow, and most of the successes relevant to atherosclerosis have involved previous biochemical knowledge of the underlying gene (a "candidate gene" strategy). One approach to the problem is to use naturally occurring variations in mice or rats, which simplifies the analysis. This is expected to provide information about a subset of the genetic variation that contributes to disease susceptibility in humans.


*    The Quantitative Trait Locus Approach
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *The Quantitative Trait Locus...
down arrowMapping Genes for...
 down arrowFrom QTL to Gene...
 down arrowThe Road Ahead
 down arrowConclusions
 down arrowReferences
 
Like humans, inbred strains show genomic sequence variations every few thousand bases, which add up to hundreds of thousands across the genome. Most of these are inconsequential, but those that do influence gene expression or function are the basis for the variation in disease susceptibility (and all other genetically based traits) that is observed among strains. Similarly, such genetic variation in humans is also the basis for the differential disease susceptibility that individuals exhibit.

Using the quantitative trait locus (QTL) analysis approach has allowed the mapping of those specific variations that are responsible for differences in atherosclerosis susceptibility and other related traits. The overall strategy for this approach involves using either F2 or N2 mice generated from a cross (Figure 1) or recombinant inbred (RI) strains. Various sets of RI strains were the main source used for identifying loci that underlie atherosclerosis and related traits before the advent of the molecular and statistical tools required for analyzing a cross. Each RI strain is in fact inbred and has been developed from intercrossing 2 parental strains for 20 generations, during which time the genomes of the progenitors are broken into homozygous intervals of different length. By comparing the distribution of a trait (eg, atherosclerosis) in the strains from 1 RI set of animals with the distribution of the polymorphic genetic markers already typed for those strains, chromosomal loci that segregate with the trait of interest can be identified. In general, RI mapping has had low power and precision to detect QTLs, mainly owing to the small number of available strains in each set. Recently, Williams et al4 published a dense map for all RI sets that share C57BL/6J as a parental strain, which might provide a tool for RI mapping of some complex traits in the future.



View larger version (32K):
[in this window]
[in a new window]
  		Figure 1. The QTL approach: from mouse to human. QTL studies begin with a cross between 2 inbred strains (eg, C57BL/6J [B6] and CAST/Ei [CAST]) that differ in their susceptibility to the trait of interest (A). Statistical analysis of the correlation between phenotypes of F2 progeny and the genomic regions that they inherited from the parental strains identifies the QTL, in this case, coincident loci for aortic lesions and insulin levels on the middle of chromosome 6 (B). This is represented in graphical form by LOD scores, where the highest point of the curve is the most likely location of the underlying gene. Arrows along the x axis depict genetic markers used to genotype the F2 animals. A congenic strain is then constructed by repeated backcrossing of an F1 animal to 1 of the parental strains (ie, B6), with selection of the chromosomal segment from the other parent (ie, CAST) that encompasses the QTL (C). Phenotyping the congenic strain for the trait(s) originally identified in linkage analysis confirms the locus (D). The underlying gene can be identified by testing positional candidate genes in the locus with either functional studies or transgenic models, in this example, 5-LO–knockout mice (E). The human ortholog of the gene (5-LO) can then be examined in human studies with family-based or case-control study designs (F).

In recent years, investigators have initiated QTL studies with crosses between inbred strains that differ in their susceptibility to atherosclerosis. Even though the use of this approach to dissect complex traits is still a long and laborious undertaking, the development of large numbers of genetic markers in mice has allowed the identification of some important genes for atherosclerosis (described later). QTL studies begin with construction of a cross between 2 selected inbred mouse strains, typically differing in expression of the primary trait of interest. The offspring of the initial mating (F1 generation) are either crossed back to 1 of the parental strains (backcross) or are themselves mated (intercross) to create an F2 generation (Figure 1A). Although the F1 mice are genetically identical, having 1 chromosome from each parent, the backcross, or F2, mice are each genetically unique. This is caused by independent segregation of chromosomes and crossovers that occur in the F1 meiotic process, which leads to combinations of genes from the original parental strains. Because these recombined regions are inherited as relatively large segments of chromosomes, the parental origins of each portion of the genome can be determined by using polymorphic markers that distinguish the parental strains. QTL analysis basically analyzes whether the measured trait varies significantly across the population on the basis of the parental genotype at any given location in the genome, in the same manner as described for RI mapping. Polymorphic markers are selected to cover the entire genome at regular intervals. Specific software is available for this analysis, and statistical standards have been established to determine the significance of the results. When positive, the data are frequently presented as a graph with a curve representing the statistical likelihood, represented by a log-of-the odds (LOD) score, of a genetic effect across the length of the chromosome (Figure 1B). For an F2 intercross, peak LOD scores >2.8 and 4.3 are taken to represent suggestive and significant evidence for linkage, respectively, although empirical significance levels can be generated for each data set by using permutation analysis. There will be a particular location along the chromosome where the likelihood of a genetic effect is greatest, referred to as the peak. From the data, a region of the chromosome on either side of the peak can be defined, within which there is a 95% or 99% statistical likelihood that the underlying gene will be present. QTL mapping in mice has considerable power to map genes for multigenic traits, by at least an order of magnitude greater than in human studies.

Typically, the regions identified are relatively large and encompass several hundred genes across millions of base pairs. However, once the genes have been mapped to chromosomal regions, each of those particular genetic intervals can be isolated on a common genetic background as a "congenic strain," which simplifies the genetics for further analysis.5 This is accomplished by repeated backcrossing of an F1 animal to 1 of the parental strains and selecting at each generation only those individual animals that carry the QTL region from the opposite parent for further study. After 10 or more backcross generations, a congenic strain is created in which the genome is composed entirely of the background strain, with the exception of the region that encompasses the QTL, which is derived from the donor strain (Figure 1C). By phenotyping these animals for the trait(s) that was initially identified in the QTL analysis, such congenic strains allow confirmation of the mapping studies (Figure 1D) and, in essence, "mendelize" the complex trait, making fine mapping to {approx}1 Mb feasible. Examination of genes located in the finely mapped region, either with transgenic/knockout animals or through functional experiments, can then identify the underlying gene (Figure 1E). Ultimately, the human orthologs of such genes can be examined in populations comprising either families or patient cases and matched controls (Figure 1F).

A key aspect of this approach is that it does not require any foreknowledge of the affected gene(s). QTL mapping therefore offers the possibility of identifying entirely novel genes that might otherwise not have been considered. Because a gene product is part of a biologic pathway, identifying 1 member might lead to elucidation of other, interacting genes.


*    Mapping Genes for Atherosclerosis in Mice
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowThe Quantitative Trait Locus...
 *Mapping Genes for...
down arrowFrom QTL to Gene...
 down arrowThe Road Ahead
 down arrowConclusions
 down arrowReferences
 
In the 1960s and 1970s, a number of investigators, including Wissler and colleagues (Vesselinovitch and Wissler,6 Vesselinovitch et al7) developed diets capable of inducing mild hyperlipidemia when fed to mice. When maintained on these diets for several months, certain strains, but not others, developed fatty streak lesions in the proximal aorta.8 In the early 1980s, several groups characterized lipoproteins in mice and demonstrated significant genetic variations in lipoprotein levels and structures among inbred strains.9,10 In the mid-1980s, Paigen and colleagues (Paigen et al,11,12 Nishima et al13) modified the original Thompson diet and refined the methods for evaluation of aortic lesions. In the early 1990s, transgenic technologies led to the development of mouse models that can develop large, advanced lesions, in contrast to the fatty streak lesions observed after feeding of the atherogenic diets to wild-type mice (reviewed in Breslow14). As yet, robust mouse models for lesion rupture and thrombosis have not been developed, but recent observations by several laboratories suggest that apoE-null or LDL receptor (LDLR)–null mice can develop lesions that share many of the features of advanced human lesions and that might be capable of rupture.15–18 Molecular studies have also suggested potential mechanisms that could contribute to unstable plaque formation in mice.19–21

The first linkage studies of atherosclerosis susceptibility in mice were carried out with RI strains derived from susceptible strains, such as C57BL/6J, and resistant strains, such as C3H/HeJ, BALB/cJ, and A/J. These studies suggested that lesions were controlled by a small number of major genes, designated Ath1, Ath2, and Ath3.12,22–24 Subsequent studies indicated a more complex picture.25–29 As discussed later, the HDL component of the Ath1 phenotype proved to be caused by polymorphisms of apoA-II.

Numerous QTL studies of atherosclerosis have now been reported from large genetic crosses between a variety of inbred strains of mice, maintained on either atherogenic diets or bred onto sensitized genetics backgrounds (such as apoE-null or LDLR-null; Table 112,22,24,30–38). A number of loci with highly significant evidence of linkage have been identified (Table 1 and Figure 2), and thus far, these studies have led to the identification of 2 genes involved in atherosclerosis (discussed subsequently).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Atherosclerosis Loci Identified From QTL Studies in Mice



View larger version (21K):
[in this window]
[in a new window]
  		Figure 2. Loci identified for atherosclerosis in mice and corresponding syntenic regions in humans. Loci with significant or suggestive LOD scores are shown with white or hatched boxes, respectively. Gray boxes correspond to loci identified from RI strain mapping. Black boxes to the left of each chromosome represent syntenic regions in the mouse of human loci that affect premature coronary heart disease (chromosomes 2 and X; stroke (chromosome 5; and coronary artery calcification (chromosomes 6 and 10. Information on the location of each syntenic region was obtained from the Mouse Genome Server at the Welcome Trust at Sanger Institute (www.ensembl.org/Mus_musculus). The name of each locus, along with proximal and distal flanking markers, are on either side of the chromosome. The cM position of each marker was obtained from the Whitehead Institute database (www-genome.wi.mit.edu/). Genes identified by the QTL approach are boxed (apoA-II; 5-LO; and LTA, lymphotoxin-{alpha}).

Genetic studies in mice have also revealed information about pathways that contribute to genetic susceptibility to atherosclerosis, particularly in relation to lipid oxidation27 and inflammation.29,39 It is noteworthy that most of the loci for atherosclerosis identified in mice do not influence plasma lipid levels, blood pressure, or other systemic risk factors (see references in Table 1). This suggests the existence of important genetic factors that act at the cellular level, presumably by influencing vascular cells or leukocytes that infiltrate the vessel wall.

Most of the loci identified in the various crosses are unique (Table 1 and Figure 2). This is somewhat unexpected, if one assumes that genetic variations are common to different inbred strains of mice. One possible explanation for this observation is that experimental designs can influence the detection of loci; for example, the loci identified might depend on whether atherosclerosis is induced by feeding an atherogenic diet or by using a sensitized genetic background. Whether a particular locus attains statistical significance will also depend on the strength and number of loci that segregate in that cross. In any case, it appears that among the various inbred strains of mice, there exist many variations that contribute to lesion development. Needless to say, the genetic complexity observed in mice underscores the difficulties that geneticists have had in identifying genes for atherosclerosis in humans.

Pathologic studies in humans have revealed a great deal of variation in advanced atherosclerotic lesions and in the processes associated with myocardial infarction.40 Most genetic studies carried out in mice thus far have only examined lesion size, usually by quantifying lipid staining near the aortic root. Studies of lesion development at other sites (the distal aorta or the innominate artery, for example) might reveal distinct genetic influences.41 Curiously, few advanced lesions are observed in the coronary arteries in mouse models. In addition to lesion size, other parameters relevant to atherosclerosis, such as cellular composition, calcification, and lesion-related aneurysms, also vary among inbred strains.

The fact that many common variations with dramatic effects on lesion development occur among inbred strains also has an important implication for reverse genetics strategies. Gene targeting is frequently performed on 1 genetic background (usually strain 129), and the mutant allele is then bred onto a separate background (frequently, strain C57BL/6J). During the breeding in this particular example, sequences flanking the targeted gene from strain 129 will be retained in the new congenic strain that is on a C57BL/6J background, and if only 4 or 5 generations of backcrossing are used, these flanking regions can be 10 or more centimorgans (cM) in size (20 million or more base pairs). If this flanking region contains a polymorphism that affects atherosclerosis, an incorrect conclusion regarding the function of the targeted gene might be drawn. This problem also applies to other traits relevant to atherosclerosis, such as plasma lipid metabolism and blood pressure, because many common variations also influence these traits.

Although the mouse is clearly the most useful mammal for genetic studies, the rat, the classic mammal for physiologic studies, is also proving to be useful for examining certain traits relevant to atherosclerosis, particularly diabetes, hypertension, and the metabolic syndrome.42 For example, with QTL analysis, the CD36 and ACE2 genes were recently shown to cause insulin resistance and defective heart functions, respectively, in different rat models of hypertension.43,44 Rabbit models have also been used widely for studies of atherosclerosis but are not as well developed for genetic studies.45


*    From QTL to Gene to Humans
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowThe Quantitative Trait Locus...
 up arrowMapping Genes for...
 *From QTL to Gene...
down arrowThe Road Ahead
 down arrowConclusions
 down arrowReferences
 
The first gene to be identified as contributing to atherosclerosis susceptibility from genetic studies in mice was Apoa2, which encodes apoA-II, an abundant component of HDL. Polymorphisms of the gene among different mouse strains determine apoA-II production or turnover,25,46 and a congenic strain that contains an allele for high levels of apoA-II exhibited increased atherosclerosis.26 Subsequent transgenic studies with both mouse apoA-II47 and human apoA-II48 indicated that apoA-II–rich HDL promotes atherogenesis. This might be due to the reduced antioxidant potential that apoA-II–enriched HDL exhibits.49,50 These observations have also been extended to humans, in whom increased apoA-II levels have been associated with metabolic disorders.51

Ultimately, the goal of identifying genes for atherosclerosis in mice is to extrapolate those results to studies in humans and to develop novel diagnostic and therapeutic strategies. Studies of the Artles locus on chromosome 6 provide such an example (Figure 1). Initially, Artles was identified in an F2 cross between inbred strains C57BL/6J and CAST/Ei and exhibited a highly significant LOD score of 6.7 (Figure 1B).36 Interestingly, there was coincident linkage of insulin levels with this locus, raising the possibility that the underlying gene has pleiotropic effects on atherosclerosis and other related metabolic traits (Figure 1B). Subsequently, a congenic strain was developed to confirm the functional importance of the QTL and to identify the underlying gene that causes resistance to lesion formation. Congenic animals carrying the middle region of chromosome 6 derived from CAST/Ei (Figure 1C) confirmed the phenotype of Artles because these mice exhibited dramatic resistance to aortic lesion formation and had lower insulin levels compared with control mice (Figure 1D). Among the candidate genes in the congenic interval was 5-lipoxygenase (5-LO), an enzyme involved in leukotriene production. 5-LO is expressed primarily in leukocytes and has been studied mainly in the context of acute, not chronic, inflammation. Based partly on the results of bone marrow transplantation experiments, which implied the involvement of monocytes/macrophages or other leukocytes, 5-LO was examined as a positional candidate. To evaluate 5-LO as a candidate gene, Mehrabian et al39 crossed 5-LO–knockout mice with LDLR-null mice and fed them a high-fat, high-cholesterol diet. Importantly, these mice exhibited a profound reduction in aortic lesion formation, despite having cholesterol levels exceeding 500 mg/dL (Figure 1E). Conservative amino acid substitutions at the 3' end of the protein were also identified between CAST/Ei and C57BL/6J, but it was not known whether these variations influenced 5-LO function.39 By creating the same substitutions at the conserved positions in the human enzyme, Habenicht and colleagues (Kuhn et al52) have recently tested the functionality of these amino acid changes and found that the CAST/Ei form of 5-LO has a marked decrease in activity and expression levels. Taken together, these studies provide strong evidence that 5-LO is the gene that underlies Artles and demonstrate the power of the QTL approach for identifying genes associated with atherosclerosis.

In preliminary studies of a human population, there is evidence to suggest that genetic variation in the 5-LO gene also affects similar phenotypes in humans. For example, a promoter polymorphism consisting of a variable number of Sp1 transcription factor binding sites was associated with carotid intima-media thickness, an accepted surrogate marker for atherosclerosis. Specifically, intima-media thickness in those individuals homozygous for either the 3 or 4 allele (D alleles) of the polymorphism was significantly increased, by nearly 100 µm, compared with individuals with other genotypes.53 Furthermore, the same individuals also exhibited significantly higher levels of insulin, C-reactive protein, and interleukin-6. These results are consistent with the observations in 5-LO–deficient mice and support the concept that 5-LO has pleiotropic effects on the development of atherosclerosis, as well as known risk factors associated with it. Pharmacologic inhibitors of 5-LO and other enzymes in the leukotriene synthesis pathway are presently available, raising the possibility of potentially novel therapeutic strategies.


*    The Road Ahead
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowThe Quantitative Trait Locus...
 up arrowMapping Genes for...
 up arrowFrom QTL to Gene...
 *The Road Ahead
down arrowConclusions
 down arrowReferences
 
A major impact of the mouse on our understanding of atherosclerosis has involved its genetic manipulation (ie, transgenic and knockout models) to examine mechanistic questions. However, studies of naturally occurring variations in the mouse, such as those described earlier, have tremendous potential to reveal new genes and pathways. Thus far, many loci for atherosclerosis-related traits have been mapped, but few genes have been identified. Recently, there has been important progress in the development of genomics and bioinformatics tools that will accelerate this process (Table 2). It seems likely that, as we enter the postgenome era of elucidating gene function, combined genetic/genomic approaches will prove increasingly useful for the identification of novel pathways relevant to atherosclerosis.44,54–58


View this table:
[in this window]
[in a new window]
  		TABLE 2. Novel Tools for Accelerated Gene Discovery

First and foremost, the currently available sequence of 5 mouse strains will allow rapid screening of candidate genes within QTLs and congenic regions. Once the QTL has been narrowed to several hundred kilobases, the entire sequence can be downloaded and examined to search for both known and unknown genes as candidates.

Recent studies have also identified numerous polymorphisms that differ among 8 strains, adding further to the tools that geneticists have at their disposal for gene identification.59,60 If the fine-mapping example described earlier were used in a cross between C57BL/6J and DBA/2J, for example, the available genomics resources would allow all of the nucleotide substitutions between C57BL/6J and DBA/2J in that region, as well as the entire sequence, to be determined. By prioritizing those genetic variations that occur in or near genes, researchers will be able to focus their effort on the most likely genetic causes first.

Among the important new developments is the availability of genome-wide congenic strains.61,62 As described earlier, once a QTL has been identified, congenic strains are created through repeated backcrossing, which can take 2 to 4 years, even with marker-assisted breeding. However, 3 panels of congenic strains that span the genome contiguously have already been constructed between C57BL/6J and A/J, C57BL/6J and CAST/Ei, and C57BL/6J B6 and DBA/2J. These resources will be of immense use for atherosclerosis-related QTLs, because rather than creating a congenic strain for each identified locus, the desired strain(s) can be obtained from the corresponding panel, and one can directly proceed to confirming the QTL and fine mapping.

The feasibility of performing large-scale arrays for RNA expression in affected tissues is also highly complementary to QTL mapping. As demonstrated recently, traditional QTL analysis when combined with expression array experiments is an extremely powerful approach and yields tremendous insight into the genetic complexity that underlies common diseases.63 In essence, measuring transcript abundances in specific tissues can be thought of as measuring any other quantitative trait (eg, cholesterol), except that microarray technology allows the simultaneous quantification of thousands of genes (ie, traits). Analogous to how QTLs for lipid levels or atherosclerosis have been identified in mouse crosses, QTLs have also now been identified for mRNA expression (eQTLs).63 In the future, therefore, the criteria for prioritizing positional candidates will also include those genes that yield eQTLs over their own physical location, the linkage of which is coincident with the "clinical" QTL that was originally identified. On another level, by performing concurrent measurement and analysis of multiple traits, gene-gene interactions can be identified, including a possible common genetic basis for apparently diverse traits, such as bone density and lipid metabolism.64 This can be performed with combinations of clinical traits and/or expression array traits, adding further to the wealth of knowledge that this approach is likely to provide.

Recently, the in vivo use of small, interfering RNA molecules (siRNA) to attenuate gene expression has come to the forefront and has the potential to allow rapid screening of positional candidate genes. This novel technique involves the injection of short, double-stranded RNA oligonucleotides into mice through the tail vein under high hydrostatic pressure.65,66 The siRNA oligonucleotides, which are homologous to a target gene, are taken up by different tissues (the liver is a particularly good tissue) and cause the selective degradation of that gene’s mRNA. Compared with the time and expense it takes to create transgenic or knockout animal strains, siRNA strategies hold tremendous promise for functional testing of candidate genes. However, a major drawback is the short and transient inhibition of gene expression, on the order of 24 to 48 hours. Thus, for traits such as atherosclerosis or obesity, which can take months to develop, the use of siRNA might not be entirely feasible.


*    Conclusions
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowThe Quantitative Trait Locus...
 up arrowMapping Genes for...
 up arrowFrom QTL to Gene...
 up arrowThe Road Ahead
 *Conclusions
down arrowReferences
 
Common forms of atherosclerosis have a very complex etiology, and because of this complexity, it has proven difficult to apply the mapping strategies that have revolutionized our understanding of mendelian disorders. QTL approaches in mice offer a viable alternative to the problem. The main difficulty encountered in this approach has been the challenge of fine mapping to reduce the number of positional candidate genes. Several new tools in mouse genetics promise to accelerate the identification of genes that underlie QTLs. Ultimately, the identification of atherosclerosis genes (in both mice and humans) will lead to a better understanding of the pathophysiologic processes that are perturbed in and are manifested as disease and to the focused discovery of novel therapeutic agents and strategies.

Received May 8, 2003; accepted July 22, 2003.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowThe Quantitative Trait Locus...
 up arrowMapping Genes for...
 up arrowFrom QTL to Gene...
 up arrowThe Road Ahead
 up arrowConclusions
 *References
 

  1. Lusis AJ, Weinreb A, Drake TA. Genetics of atherosclerosis. In: Topol EJ, ed. Textbook of Cardiovascular Disease. Philadelphia, Pa: Lippincott-Raven Publishers; 1998: 2389–2413.
  2. Lusis AJ. Atherosclerosis. Nature. 2000; 407: 233–241.[CrossRef][Medline] [Order article via Infotrieve]
  3. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet. 1995; 11: 241–247.[CrossRef][Medline] [Order article via Infotrieve]
  4. Williams RW, Gu J, Qi S, Lu L. The genetic structure of recombinant inbred mice: high-resolution consensus maps for complex trait analysis. Genome Biol. 2001; 2: RESEARCH0046. Epub 2001 Oct 22.
  5. Darvasi A. Experimental strategies for the genetic dissection of complex traits in animal models. Nat Genet. 1998; 18: 19–24.[CrossRef][Medline] [Order article via Infotrieve]
  6. Vesselinovitch D, Wissler RW. Experimental production of atherosclerosis in mice, 2: effects of atherogenic and high-fat diets on vascular changes in chronically and acutely irradiated mice. J Atheroscler Res. 1968; 8: 497–523.[Medline] [Order article via Infotrieve]
  7. Vesselinovitch D, Wissler RW, Doull J. Experimental production of atherosclerosis in mice, 1: effect of various synthetic diets and radiation on survival time, food consumption and body weight in mice. J Atheroscler Res. 1968; 8: 483–495.[Medline] [Order article via Infotrieve]
  8. Roberts A, Thompson JS. Inbred mice and their hybrids as an animal model for atherosclerosis research. Adv Exp Med Biol. 1976; 67: 313–327.[Medline] [Order article via Infotrieve]
  9. LeBoeuf RC, Puppione DL, Schumaker VN, Lusis AJ. Genetic control of lipid transport in mice, I: structural properties and polymorphisms of plasma lipoproteins. J Biol Chem. 1983; 258: 5063–5070.[Abstract/Free Full Text]
  10. Lusis AJ, Taylor BA, Wangenstein RW, LeBoeuf RC. Genetic control of lipid transport in mice, II: genes controlling structure of high density lipoproteins. J Biol Chem. 1983; 258: 5071–5078.[Abstract/Free Full Text]
  11. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987; 68: 231–240.[CrossRef][Medline] [Order article via Infotrieve]
  12. Paigen B, Nesbitt MN, Mitchell D, Albee D, LeBoeuf RC. Ath-2, a second gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Genetics. 1989; 122: 163–168.[Abstract/Free Full Text]
  13. Nishina PM, Verstuyft J, Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res. 1990; 31: 859–869.[Abstract]
  14. Breslow JL. Mouse models of atherosclerosis. Science. 1996; 272: 685–688.[Abstract]
  15. Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G, Schwartz SM. Advanced atherosclerotic lesions in the innominate artery of the apoE knockout mouse. Arterioscler Thromb Vasc Biol. 2000; 20: 2587–2592.[Abstract/Free Full Text]
  16. Calara F, Silvestre M, Casanada F, Yuan N, Napoli C, Palinski W. Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J Pathol. 2001; 195: 257–263.[CrossRef][Medline] [Order article via Infotrieve]
  17. Johnson JL, Jackson CL. Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis. 2001; 154: 399–406.[CrossRef][Medline] [Order article via Infotrieve]
  18. Song L, Leung C, Schindler C. Lymphocytes are important in early atherosclerosis. J Clin Invest. 2001; 108: 251–259.[CrossRef][Medline] [Order article via Infotrieve]
  19. Caligiuri G, Levy B, Pernow J, Thoren P, Hansson GK. Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Proc Natl Acad Sci U S A. 1999; 96: 6920–6924.[Abstract/Free Full Text]
  20. von der Thusen JH, van Vlijmen BJ, Hoeben RC, Kockx MM, Havekes LM, van Berkel TJ, Biessen EA. Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation. 2002; 105: 2064–2070.[Abstract/Free Full Text]
  21. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II–induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003; 23: 483–488.[Abstract/Free Full Text]
  22. Paigen B, Mitchell D, Reue K, Morrow A, Lusis AJ, LeBoeuf RC. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc Natl Acad Sci U S A. 1987; 84: 3763–3767.[Abstract/Free Full Text]
  23. Stewart-Phillips JL, Lough J, Skamene E. Genetically determined susceptibility and resistance to diet-induced atherosclerosis in inbred strains of mice. J Lab Clin Med. 1988; 112: 36–42.[Medline] [Order article via Infotrieve]
  24. Stewart-Phillips JL, Lough J, Skamene E. ATH-3, a new gene for atherosclerosis in the mouse. Clin Invest Med. 1989; 12: 121–126.[Medline] [Order article via Infotrieve]
  25. Doolittle MH, LeBoeuf RC, Warden CH, Bee LM, Lusis AJ. A polymorphism affecting apolipoprotein A-II translational efficiency determines high density lipoprotein size and composition. J Biol Chem. 1990; 265: 16380–16388.[Abstract/Free Full Text]
  26. Mehrabian M, Qiao JH, Hyman R, Ruddle D, Laughton C, Lusis AJ. Influence of the apoA-II gene locus on HDL levels and fatty streak development in mice. Arterioscler Thromb. 1993; 13: 1–10.[Abstract]
  27. Liao F, Andalibi A, Qiao JH, Allayee H, Fogelman AM, Lusis AJ. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest. 1994; 94: 877–884.
  28. Machleder D, Ivandic B, Welch C, Castellani L, Reue K, Lusis AJ. Complex genetic control of HDL levels in mice in response to an atherogenic diet: coordinate regulation of HDL levels and bile acid metabolism. J Clin Invest. 1997; 99: 1406–1419.[Medline] [Order article via Infotrieve]
  29. Shi W, Wang NJ, Shih DM, Sun VZ, Wang X, Lusis AJ. Determinants of atherosclerosis susceptibility in the C3H and C57BL/6 mouse model: evidence for involvement of endothelial cells but not blood cells or cholesterol metabolism. Circ Res. 2000; 86: 1078–1084.[Abstract/Free Full Text]
  30. Phelan SA, Beier DR, Higgins DC, Paigen B. Confirmation and high resolution mapping of an atherosclerosis susceptibility gene in mice on chromosome 1. Mamm Genome. 2002; 13: 548–553.[CrossRef][Medline] [Order article via Infotrieve]
  31. Mu JL, Naggert JK, Svenson KL, Collin GB, Kim JH, McFarland C, Nishina PM, Levine DM, Williams KJ, Paigen B. Quantitative trait loci analysis for the differences in susceptibility to atherosclerosis and diabetes between inbred mouse strains C57BL/6J and C57BLKS/J. J Lipid Res. 1999; 40: 1328–1335.[Abstract/Free Full Text]
  32. Purcell MK, Mu JL, Higgins DC, Elango R, Whitmore H, Harris S, Paigen B. Fine mapping of Ath6, a quantitative trait locus for atherosclerosis in mice. Mamm Genome. 2001; 12: 495–500.[CrossRef][Medline] [Order article via Infotrieve]
  33. Paigen B. Genetics of responsiveness to high-fat and high-cholesterol diets in the mouse. Am J Clin Nutr. 1995; 62: 458S–462S.[Abstract/Free Full Text]
  34. Pitman WA, Hunt MH, McFarland C, Paigen B. Genetic analysis of the difference in diet-induced atherosclerosis between the inbred mouse strains SM/J and NZB/BINJ. Arterioscler Thromb Vasc Biol. 1998; 18: 615–620.[Abstract/Free Full Text]
  35. Dansky HM, Shu P, Donavan M, Montagno J, Nagle DL, Smutko JS, Roy N, Whiteing S, Barrios J, McBride TJ, Smith JD, Duyk G, Breslow JL, Moore KJ. A phenotype-sensitizing Apoe-deficient genetic background reveals novel atherosclerosis predisposition loci in the mouse. Genetics. 2002; 160: 1599–1608.[Abstract/Free Full Text]
  36. Mehrabian M, Wong J, Wang X, Jiang Z, Shi W, Fogelman AM, Lusis AJ. Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res. 2001; 89: 125–130.[Abstract/Free Full Text]
  37. Colinayo VV, Qiao J-H, Wang X, Krass KL, Schadt E, Lusis AJ, Drake TA. Novel genetic loci for diet-induced atherosclerotic lesions and plasma lipids in mice. Mamm Genome. 2003; 14: 464–471.[CrossRef][Medline] [Order article via Infotrieve]
  38. Welch CL, Bretschger S, Latib N, Bezouevski M, Guo Y, Pleskac N, Liang CP, Barlow C, Dansky H, Breslow JL, Tall AR. Localization of atherosclerosis susceptibility loci to chromosomes 4 and 6 using the Ldlr knockout mouse model. Proc Natl Acad Sci U S A. 2001; 98: 7946–7951.[Abstract/Free Full Text]
  39. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ, Shih W. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002; 91: 120–126.[Abstract/Free Full Text]
  40. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000; 20: 1262–1275.[Free Full Text]
  41. Reardon CA, Blachowicz L, White T, Cabana V, Wang Y, Lukens J, Bluestone J, Getz GS. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001; 21: 1011–1016.[Abstract/Free Full Text]
  42. Stoll M, Cowley AW Jr, Tonellato PJ, Greene AS, Kaldunski ML, Roman RJ, Dumas P, Schork NJ, Wang Z, Jacob HJ. A genomic-systems biology map for cardiovascular function. Science. 2001; 294: 1723–1726.[Abstract/Free Full Text]
  43. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet. 1999; 21: 76–83.[CrossRef][Medline] [Order article via Infotrieve]
  44. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002; 417: 822–828.[CrossRef][Medline] [Order article via Infotrieve]
  45. Thiery J, Teupser D, Walli AK, Ivandic B, Nebendahl K, Stein O, Stein Y, Seidel D. Study of causes underlying the low atherosclerotic response to dietary hypercholesterolemia in a selected strain of rabbits. Atherosclerosis. 1996; 121: 63–73.[CrossRef][Medline] [Order article via Infotrieve]
  46. Purcell-Huynh DA, Weinreb A, Castellani LW, Mehrabian M, Doolittle MH, Lusis AJ. Genetic factors in lipoprotein metabolism: analysis of a genetic cross between inbred mouse strains NZB/BINJ and SM/J using a complete linkage map approach. J Clin Invest. 1995; 96: 1845–1858.
  47. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993; 261: 469–472.[Abstract/Free Full Text]
  48. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991; 353: 265–267.[CrossRef][Medline] [Order article via Infotrieve]
  49. Castellani LW, Navab M, Van Lenten BJ, Hedrick CC, Hama SY, Goto AM, Fogelman AM, Lusis AJ. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest. 1997; 100: 464–474.[Medline] [Order article via Infotrieve]
  50. Castellani LW, Lusis AJ. ApoA-II versus apoA-I: two for one is not always a good deal. Arterioscler Thromb Vasc Biol. 2001; 21: 1870–1872.[Free Full Text]
  51. Allayee H, Castellani LW, Cantor RM, de Bruin TW, Lusis AJ. Biochemical and genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia. Circ Res. 2003; 92: 1262–1267.[Abstract/Free Full Text]
  52. Kuhn H, Anton M, Gerth C, Habenicht A. Amino acid differences in the deduced 5-lipoxygenase sequence of CAST atherosclerosis-resistance mice confer impaired activity when introduced into the human ortholog. Arterioscler Thromb Vasc Biol. 2003; 23: 1072–1076.[Abstract/Free Full Text]
  53. Allayee H, Dwyer JH, Fan J, Dwyer KM, Mar RA, Lusis AJ, Mehrabian M. A promoter polymorphism of 5-lipoxygenase is associated with carotid atherosclerosis in the human population. Am J Hum Genet. 2002; 71: S435. Abstract.
  54. Allayee H, Laffitte BA, Lusis AJ. Biochemistry: an absorbing study of cholesterol. Science. 2000; 290: 1709–1711.[Free Full Text]
  55. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000; 290: 1771–1775.[Abstract/Free Full Text]
  56. Peterfy M, Phan J, Xu P, Reue K. Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. Nat Genet. 2001; 27: 121–124.[CrossRef][Medline] [Order article via Infotrieve]
  57. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001; 294: 169–173.[Abstract/Free Full Text]
  58. Bodnar JS, Chatterjee A, Castellani LW, Ross DA, Ohmen J, Cavalcoli J, Wu C, Dains KM, Catanese J, Chu M, Sheth SS, Charugundla K, Demant P, West DB, de Jong P, Lusis AJ. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat Genet. 2002; 30: 110–116.[CrossRef][Medline] [Order article via Infotrieve]
  59. Wade CM, Kulbokas EJ 3rd, Kirby AW, Zody MC, Mullikin JC, Lander ES, Lindblad-Toh K, Daly MJ. The mosaic structure of variation in the laboratory mouse genome. Nature. 2002; 420: 574–578.[CrossRef][Medline] [Order article via Infotrieve]
  60. Wiltshire T, Pletcher MT, Batalov S, Barnes SW, Tarantino LM, Cooke MP, Wu H, Smylie K, Santrosyan A, Copeland NG, Jenkins NA, Kalush F, Mural RJ, Glynne RJ, Kay SA, Adams MD, Fletcher CF. Genome-wide single-nucleotide polymorphism analysis defines haplotype patterns in mouse. Proc Natl Acad Sci U S A. 2003; 100: 3380–3385.[Abstract/Free Full Text]
  61. Nadeau JH, Singer JB, Matin A, Lander ES. Analysing complex genetic traits with chromosome substitution strains. Nat Genet. 2000; 24: 221–225.[CrossRef][Medline] [Order article via Infotrieve]
  62. Iakoubova OA, Olsson CL, Dains KM, Ross DA, Andalibi A, Lau K, Choi J, Kalcheva I, Cunanan M, Louie J, Nimon V, Machrus M, Bentley LG, Beauheim C, Silvey S, Cavalcoli J, Lusis AJ, West DB. Genome-tagged mice (GTM): two sets of genome-wide congenic strains. Genomics. 2001; 74: 89–104.[CrossRef][Medline] [Order article via Infotrieve]
  63. Schadt EE, Monks SA, Drake TA, Lusis AJ, Che N, Colinayo V, Ruff TG, Milligan SB, Lamb JR, Cavet G, Linsley PS, Mao M, Stoughton RB, Friend SH. Genetics of gene expression surveyed in maize, mouse and man. Nature. 2003; 422: 297–302.[CrossRef][Medline] [Order article via Infotrieve]
  64. Drake TA, Schadt E, Hannani K, Kabo JM, Krass K, Colinayo V, Greaser LE 3rd, Goldin J, Lusis AJ. Genetic loci determining bone density in mice with diet-induced atherosclerosis. Physiol Genomics. 2001; 5: 205–215.[Abstract/Free Full Text]
  65. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature. 2002; 418: 38–39.[CrossRef][Medline] [Order article via Infotrieve]
  66. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet. 2002; 32: 107–108.[CrossRef][Medline] [Order article via Infotrieve]



This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. S. Wang, W. Shi, X. Wang, L. Velky, S. Greenlee, M. T. Wang, T. A. Drake, and A. J. Lusis
Mapping, Genetic Isolation, and Characterization of Genetic Loci That Determine Resistance to Atherosclerosis in C3H Mice
Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2671 - 2676.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
T. Hashimoto, M. Kihara, N. Imai, S.-i. Yoshida, H. Shimoyamada, H. Yasuzaki, J. Ishida, Y. Toya, Y. Kiuchi, N. Hirawa, et al.
Requirement of Apelin-Apelin Receptor System for Oxidative Stress-Linked Atherosclerosis
Am. J. Pathol., November 1, 2007; 171(5): 1705 - 1712.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
S. S. Wang, E. E. Schadt, H. Wang, X. Wang, L. Ingram-Drake, W. Shi, T. A. Drake, and A. J. Lusis
Identification of Pathways for Atherosclerosis in Mice: Integration of Quantitative Trait Locus Analysis and Global Gene Expression Data
Circ. Res., August 3, 2007; 101(3): e11 - e30.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
E. J. Topol, J. Smith, E. F. Plow, and Q. K. Wang
Genetic susceptibility to myocardial infarction and coronary artery disease
Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R117 - R123.
[Abstract] [Full Text] [PDF]

Home page
 GeneticsHome page
A. Ghazalpour, X. Wang, A. J. Lusis, and M. Mehrabian
Complex Inheritance of the 5-Lipoxygenase Locus Influencing Atherosclerosis in Mice
Genetics, June 1, 2006; 173(2): 943 - 951.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Teupser, M. Tan, A. D. Persky, and J. L. Breslow
Atherosclerosis quantitative trait loci are sex- and lineage-dependent in an intercross of C57BL/6 and FVB/N low-density lipoprotein receptor-/- mice
PNAS, January 3, 2006; 103(1): 123 - 128.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A. Ghazalpour, S. Doss, X. Yang, J. Aten, E. M. Toomey, A. Van Nas, S. Wang, T. A. Drake, and A. J. Lusis
Thematic review series: The Pathogenesis of Atherosclerosis. Toward a biological network for atherosclerosis
J. Lipid Res., October 1, 2004; 45(10): 1793 - 1805.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. J. Lusis, A. M. Fogelman, and G. C. Fonarow
Genetic Basis of Atherosclerosis: Part I: New Genes and Pathways
Circulation, September 28, 2004; 110(13): 1868 - 1873.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. Hirsch-Reinshagen, S. Zhou, B. L. Burgess, L. Bernier, S. A. McIsaac, J. Y. Chan, G. H. Tansley, J. S. Cohn, M. R. Hayden, and C. L. Wellington
Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain
J. Biol. Chem., September 24, 2004; 279(39): 41197 - 41207.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
N. Ishimori, R. Li, P. M. Kelmenson, R. Korsta